ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/pancreas/advanced-metastatic/subsequent
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Pancreas - Advanced/metastatic / Subsequent
34
trial(s) found.
NCT07678593
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (
GFH276X0201
)
anti-EGFR monoclonal antibody
pan-RAS inhibitor,tricomplex inhibitor
Cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - PASO Medical
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT07670312
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase 1b/2, Multicenter, Non-randomized, Open-label, Multiple Dose First- In-Human Study of XYA02 in Patients With Advanced Solid Tumors (
XYA02-100
)
anti-MUC1 antibody-drug conjugate
Colorectal cancer
Gastroesophageal junction adenocarcinoma
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07644559
Advanced
Phase 2
Recruiting
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201) (
VS-7375-201
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
anti-EGFR monoclonal antibody
Pancreatic adenocarcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07562152
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301) (
MAPKeeper-301
)
MEK inhibitor,deep-cyclic
antimetabolite
taxane
Pancreatic adenocarcinoma
NSW
2220 - Hurstville - GenesisCare Hurstville
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4032 - Chermside - Icon Cancer Care Chermside
4102 - Woolloongabba - Princess Alexandra Hospital
NCT07555587
Advanced
Phase 1
Not yet recruiting
A Phase Ib Trial to Evaluate the Safety and Efficacy of NRT6008 Plus Chemotherapy in Unresectable Locally Advanced Pancreatic Carcinoma (
NRTPacAU-1
)
unknown drug class
Pancreatic cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT07341737
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours (
SL-28-FIH
)
allogeneic cell therapy,unspecified mechanism
Bladder cancer
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Hepatocellular carcinoma
Kidney cancer
Lung adenocarcinoma
Lung cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07255404
Advanced
Phase 2
Recruiting
A Phase II, Multi-site, Randomized, Open-label, Trial of Pumitamig in Combination With Chemotherapy in Patients With Metastatic Pancreatic Cancer (
BNT327-09
)
bispecific PD-L1/VEGFA antibody
Pancreatic adenocarcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4217 - Benowa - Pindara Private Hospital
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT07020221
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors (
VS-7375-101
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06926075
Advanced
Phase 1 / Phase 2
Recruiting
An Adaptive Phase I/II Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
hGIIA-vimentin inhibitor
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Private Hospital
2228 - Miranda - Southside Cancer Care Centre
NCT06917079
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers (
TBBO11818-101
)
pan-KRAS inhibitor,ON/OFF-state inhibitor
Cancer
Colorectal cancer
Lung cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06914128
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.
PRMT5 inhibitor
NOT Glioblastoma
NOT High-grade glioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
NCT06910657
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06751329
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors (
DM002001
)
bispecific-ERBB3/MUC1 antibody-drug conjugate
Colorectal adenocarcinoma
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2500 - Wollongong - Cancer Care Wollongong
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Breast cancer
NOT Colorectal adenocarcinoma
NOT Gastroesophageal cancer
NOT Gastroesophageal junction adenocarcinoma
NOT Pancreatic adenocarcinoma
NOT Pancreatic cancer
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5000 - Adelaide - Cancer Research SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06465069
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (
NEXUS-01
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
anti-FR-alpha antibody-drug conjugate,topoisomerase inhibitor 1-payload
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Cancer Research SA
NCT06330064
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) (
DS7300-203
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Cutaneous melanoma
Endometrial cancer
Gastrooesophageal adenicarcoma
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
NOT Sarcoma
Ovarian cancer
Pancreatic adenocarcinoma
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06244771
Advanced
Phase 1 / Phase 2
Recruiting
An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (
PROSPER
)
KRAS G12C inhibitor,ON/OFF-state inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4215 - Southport - Tasman Oncology
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Bladder cancer
Breast cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Sarcoma
Small-cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05093231
Advanced
Phase 2
Recruiting
A Phase II Study Combining Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma (PDA) Patients With Mismatch Repair Deficiency or Tumour Mutation Burden > 4 Mutations/Mb (
PemOla
)
PARP1/2 inhibitor
anti-PD-1 monoclonal antibody
Pancreatic cancer
VIC
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04429542
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (
BCA101X1101
)
bifunctional EGFR/TGF-beta fusion protein
Anal squamous cell carcinoma
Carcinoma
Colorectal cancer
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Squamous cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
ACTRN12626001051336
Advanced
Not Applicable
Not yet recruiting
Impact of intra-tumour phosphorus-32 implantation in metastatic pancreatic adenocarcinoma
brachytherapy
Pancreatic cancer
ACTRN12625000203459
Advanced
Phase 1 / Phase 2
Recruiting
An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (
ENG19
)
EnGeneIC Dream Vector-nanocells-delivered,EGFR-targeting
Colorectal cancer
Kidney cancer
Lung cancer
Mesothelioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
ACTRN12624001067561
Advanced
Not Applicable
Not yet recruiting
Evaluate the effectiveness of implementing a supportive care navigation tool for people diagnosed with pancreatic cancer.
Pancreatic cancer
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12607000323426
Advanced
Recruiting
Effects of fish oil containing eicosapentaenoic acid (EPA) on weight loss and cachexia in pancreatic cancer patients undergoing cancer chemotherapy.
omega-3 fatty acid
Pancreatic adenocarcinoma
NCT05642949
Advanced
Phase 1 / Phase 2
Unknown
Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors (
MHB036C-CP001EN
)
anti-Trop2 antibody-drug conjugate
Breast cancer
Endometrial cancer
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal squamous cell carcinoma
Ovarian cancer
Pancreatic adenocarcinoma
Prostate cancer
Small-cell lung cancer
Solid tumour
Sweat gland carcinoma
Urothelial carcinoma
VIC
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT03906331
Advanced
Approved for marketing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
RET-selective inhibitor
RET inhibitor
Selpercatinib
cancer therapy
cancer therapy,RET-targeting
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Non-small cell lung cancer
Pancreatic cancer
Papillary thyroid cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (27)
Not yet recruiting (5)
Unknown (1)
Approved for marketing (1)
Recruitment Country and State
NSW (22)
VIC (19)
QLD (14)
SA (13)
WA (9)
TAS (1)
NZ (1)
Phase
Phase 1 (9)
Phase 1 / Phase 2 (14)
Phase 2 (6)
Phase 3 (1)
Trial Type
Advanced (34)
Cancer Therapy Class
PD-1/PD-L1
29%
PD-1
26%
EGFR
15%
KRAS
15%
PD-L1
6%
VEGFA
6%
Trop2
6%
SMO
6%
VEGF
6%
B7H3
6%
MET
6%
MUC1
3%
MEK
3%
hGIIA-vimentin
3%
PI3Kalpha
3%
PRMT5
3%
ERBB2
3%
ER alpha
3%
oestrogen axis
3%
Nectin4
3%
FR-alpha
3%
ERBB3
3%
PARP
3%
IL-2
3%
CCR8
3%
RET
3%
Facility
2109 - North Ryde - Macquarie University Hospital (6)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
3168 - Clayton - Monash Medical Centre (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
6009 - Nedlands - Linear Clinical Research (4)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
3199 - Frankston - Peninsula Health Frankston Hospital (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (3)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
6009 - Nedlands - One Clinical Research (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2139 - Concord - Concord Repatriation General Hospital (2)
3066 - Epping - Northern Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
4032 - Chermside - Icon Cancer Care Chermside (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
3004 - Melbourne, Southbank - Alfred Health (2)
4217 - Benowa - Pindara Private Hospital (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2170 - Liverpool - Liverpool Hospital (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
5000 - Adelaide - Cancer Research SA (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
3199 - Frankston - PASO Medical (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
2220 - Hurstville - GenesisCare Hurstville (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
2500 - Wollongong - Cancer Care Wollongong (1)
3002 - East Melbourne - Epworth Freemasons (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4215 - Southport - Tasman Oncology (1)
NA
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2060 - North Sydney - Mater Hospital (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
Cancer Type
Cancer
Gastrointestinal cancer
Solid tumour
Upper gastrointestinal cancer
Pancreatic cancer
Pancreatobiliary cancer
Thoracic cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Lung cancer
Respiratory tract cancer
Colorectal cancer
Lower gastrointestinal cancer
Gynaecological cancer
Non-small cell lung cancer
Ovarian cancer
Breast cancer
Urogenital cancer
Gastroesophageal cancer
Oesophageal cancer
Gastric cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Viral-related cancer
Cervical cancer
Head and neck squamous cell carcinoma
Endometrial cancer
Hepatobiliary cancer
Kidney cancer
Male genital cancers
Melanoma
Prostate cancer
Bladder cancer
Hepatocellular carcinoma
Skin cancer
Breast adenocarcinoma
Triple-negative breast cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Colorectal adenocarcinoma
Epithelial Ovarian Cancer
Clear cell renal cell carcinoma
Urothelial carcinoma
Carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Sarcoma
Biliary tract cancer
Cutaneous melanoma
High-grade serous ovarian cancer
Neuroendocrine carcinoma
Ovarian adenocarcinoma
Ovarian serous carcinoma
Prostate adenocarcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Oesophageal squamous cell carcinoma
Cutaneous squamous cell carcinoma
Mesothelioma
Colon adenocarcinoma
Endocrine gland cancer
Thyroid cancer
Lung adenocarcinoma
Renal pelvis cancer
Gastrooesophageal adenicarcoma
Castrate-resistant prostate cancer
Platinum resistant ovarian cancer
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
Endometrial carcinoma
Fallopian tube cancer
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Squamous non-small-cell lung cancer
dMMR solid cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Anal cancer
Anal squamous cell carcinoma
Squamous cell carcinoma
MET:alteration
MET:fusion
Sweat gland carcinoma
Differentiated thyroid carcinoma
Medullary thyroid cancer
Papillary thyroid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy